• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma


2.233 EUR 0.217 8.86%

As of 05:51:40 ET on 12/18/2014.

Snapshot for Novogen Ltd (NV9A)

Open: 2.276 Day's Range: 2.233 - 2.276 Volume: 0
Previous Close: 2.450 52wk Range: 1.267 - 4.275 1-Yr Rtn: -22.38%

Stock Chart for NV9A

No chart data available.
  • NV9A:GR 2.233
  • 1M
  • 1Y
Interactive NV9A Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NV9A

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. DAX -
Earnings Per Share (ttm) -
Est. EPS -
Est. PEG Ratio -
Market Cap (M EUR) 16.76
Shares Outstanding (M) 7.50
30 Day Average Volume 954
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/02/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NV9A

  • Revenue
  • Net Income (M/AUD)
  • Profit Margin (%)

Company Profile & Key Executives for NV9A

Novogen Limited is a medical services company which develops and markets pharmaceutical products in Australia. The Company conducts clinical trials on medications which promote the prevention and treatment of common cancers and the reversal of immune depression. The Company also develops dietary supplements, hormonal imbalance drugs, anti-inflammatory and cardiovascular drugs.

Graham Edmund KellyChairman/CEO/Exec Dir/FounderDavid BrownChief Scientific Officer
Justine StehnDir:ATM ProgramStephen PalmerDir:Degenerative Disease Program
More Company Profile & Key Executives for NV9A

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil